Pharming Group N.V.

Pharming Group N.V.

PHAR ·

Pharming Group N.V. (PHAR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Pharming Group N.V. in 2026. The next earnings report is expected on November 5, 2026.

Earnings calendar

Next earnings date

05 Nov 2026

In 76 days

EPS estimate

0.01

Revenue estimate

110.3M

Past earnings

30 Jul 2026
EPS actual
0.00 (-68.3%)
estimate 0.01
Revenue actual
90.2M (-9.4%)
estimate 99.5M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
-0.07 (-7,100.0%)
estimate 0.00
Revenue actual
72.4M (-21.3%)
estimate 92.1M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Mar 2026
EPS actual
0.07 (+366.7%)
estimate 0.02
Revenue actual
106.5M (-4.7%)
estimate 111.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
06 Nov 2025
EPS actual
0.10 (+2,122.2%)
estimate 0.00
Revenue actual
97.3M (-0.9%)
estimate 98.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Pharming Group N.V. missed consensus estimates in its latest earnings report, with EPS of USD 0.002 versus an estimate of USD 0.0063 and revenue of USD 90.2 million, 9.4% below estimates. In the prior report both EPS and revenue also fell short of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Sector
Healthcare
Industry
Biotechnology
Country
Netherlands
Exchange
Nasdaq
CEO
Fabrice Chouraqui
Employees
404
IPO date
23 Dec 2020
ISIN
NL0010391025
Website
pharming.com

Frequently asked questions

When does Pharming Group N.V. (PHAR) next report earnings?

Pharming Group N.V. (PHAR) is scheduled to report earnings on November 5, 2026.

What was Pharming Group N.V.'s most recent earnings date?

Pharming Group N.V. (PHAR) last reported earnings on July 30, 2026.

Where is Pharming Group N.V. stock listed?

Pharming Group N.V. (PHAR) is listed on Nasdaq.